About Lysosomal Storage Disorders: Summary of Product Characteristics

We have detected that your browser does not have Javascript turned on. This site is optimized for Javascript.
You may experience difficulties browsing certain parts of the site.

Genzyme Belgium

Genzyme Corporate

A disease with many faces

Healthcare Professionals

About Lysosomal Storage Disease

	History
	Biology of the lysosome
	Lysosomes and disease
	Molecular pathogenesis
	Disease progression
	Presentation & progression
	Disease management
	Diagnosis & testing
	Genetics
	Summary of Product Characteristics

Summary of Product Characteristics

MPS I – Aldurazyme®

Click here for Dutch version (PDF)
Click here for French version (PDF)

Fabry – Fabrazyme®

Click here for Dutch version (PDF)
Click here for French version (PDF)

Gaucher – Cerezyme®

Click here for Dutch version (PDF)
Click here for French version (PDF)

Pompe – Myozyme®

Click here for Dutch version (PDF)
Click here for French version (PDF)

PRINT

BOOKMARK

01/01/2007: Low bone density in Gaucher disease improves with Cerezyme®

01/05/2007: Treatment for Pompe disease now available for Belgian patients

01/03/2006: Early treatment with Fabrazyme® significantly slows progression of Fabry


	General information

	Gaucher Disease

	Fabry Disease

	MPS I Disease

	Pompe Disease



	Terms and Conditions of Use \| Privacy Policy \| © 2010 Genzyme Corporation. All rights reserved.